In vitro antagonism of rabeprazole and metronidazole upon clinical isolates of Helicobacter pylori

Chemotherapy

Volumn 55, Issue 5, 2009, Pages 308-311

  Soto, Alejandra ^a   García, Apolinaria ^a   González, Carlos L ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Antagonism; Helicobacter; Metronidazole; Rabeprazole

Indexed keywords

AMOXICILLIN; METRONIDAZOLE; RABEPRAZOLE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; DRUG EFFECT; HELICOBACTER PYLORI; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AMOXICILLIN; ANTI-BACTERIAL AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS;

EID: 67649203118     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226426     Document Type: Article

References (20)

1. McLoughlin R, O'Morain C: Effectiveness of antiinfectives. Chemotherapy 2005;51:243-246.
2. Moss SF, Malfertheiner P: Helicobacter and gastric malignancies. Helicobacter 2007;12(suppl 1):23-30.
3. Malfertheiner P, Mégraud F, O'Morian C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers E, The European Helicobacter Study Group (EHSG): Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781.
4. Egan BJ, Marzio L, O'Connor H, O'Morain C: Treatment of Helicobacter pylori infection. Helicobacter 2008;13(suppl 1):35-40.
5. Vakil N, Megraud F: Reviews in basic and clinical gastroenterology: eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001.
6. Nagata K, Sone N, Tamura T: Inhibitory activities of lanzoprazole against respiration in Helicobacter pylori. Antimicrob Agents Chemother 2001;45:1522-1527.
7. Graham DY, Shiotani A: New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5:321-331.
8. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D: Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007;39:1001-1005.
9. Lee CC, Lee VWY, Chan FKL, Ling TKW: Levofloxacin-resistant Helicobacter pylori in Hong Kong. Chemotherapy 2008;54:50-53.
10. O'Morain CA, O'Connor HJ: Is sequential therapy superior to standard triple therapy for the treatment of Helicobacter pylori infection? Nat Clin Pract Gastroenterol Hepatol 2009;6:8-9.
11. Tanaka M, Isogai E, Isogai H, Hayashi J, et al: Synergistic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002;49:1039-1040.
12. Murakami K, Okimoto T, Kodama M, Sato R, Watanabe K, Fujioka T: Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. J Clin Gastroenterol 2008;42:139-142.
13. Gisbert JP, Gonzalez L, Calvet X: Systematic review and meta-analysis: proton pump inhibitors vs ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter 2005;10:157-171.
14. Qasima A, O'Morain CA, O'Connor HJ: Helicobacter pylori eradication: role of individual therapy constituents and therapy duration. Fundam Clin Pharmacol 2009;23:43-52.
15. Kawakami Y, Akahane T, Yamaguchi M, et al: In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000;44:458-461. (Pubitemid 30060755)
16. Mirshahi F, Fowler G, Patel A, Shaw G: Omeprazole may exert both a bacteriostatic and a bacteriocidal effect on the growth of Helicobacter pylori (NCTC 11637) in vitro by inhibiting bacterial urease activity. J Clin Pathol 1998;51:220-224.
17. Tsuitsui N, Taneike I, Ohara T, Goshi S, et al: A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob Agents Chemother 2000;44:3069-3073. (Pubitemid 30803067)
18. Padol S, Yuan X, Thabaue M, et al: The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line therapies: a meta-analysis. Am J Gastroenterol 2007;101:1467-1475.
19. Zhang X-P, Wang W-H, Tian Y, Gao W, Li J: Aspirin increases susceptibility of Helicobacter pylori to metronidazole by augmenting endocellular concentration of antimicrobials. World J Gastroenterol 2009;15:919-992.
20. Bina JE, Alm RA, UriaNickelsen M, Thomas SR, Trust TJ, Hancock REW: Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. Antimicrob Agents Chemother 2000;44:248-254.